Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

- PMLiVE

EU approval for Opdivo combo in renal cell cancer

BMS one step ahead of rivals

- PMLiVE

Chinese biotechs aim PD-L1 antibody at hepatitis B

Cancer therapies could help boost patient's immune system

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

First-line ovarian approval cements AZ’s Lynparza lead

Also new data on recently approved kidney disease drug

- PMLiVE

Horizon Discovery and C4X to harness CRISPR for new cancer drugs

UK companies combine computational and genomic platforms

- PMLiVE

AZ still sees route to approval for Imfinzi in MYSTIC trial

New analysis shows opportunity in NSCLC

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

Live from Singapore: Oncology in APAC – Evaluating the opportunity for novel therapies

Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST

Research Partnership

- PMLiVE

GSK buys cancer firm Tesaro for $5.1bn

Acquisition re-establishes US commercial operations in oncology

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links